CD8A and neoplasm: For instance, butyrate and SCFA-A have been shown to potentiate the effectiveness of anti-PD-1 therapy in cancer patients by activating tumor-infiltrating GNLY+ CD8+ T cells and promoting T cell activation, respectively, as well as by inducing M1 macrophage polarization (79, 80).